Cordycepin

Pharmacology & Research

Cordycepin (3’-deoxyadenosine) is the signature nucleoside of Cordyceps militaris and the molecule behind most of cordyceps’ preclinical anticancer and anti-inflammatory reputation. Structurally it is adenosine missing its 3’-hydroxyl, and that single change defines both its mechanism and its problem. The mechanism: lacking a 3’-OH, it is incorporated into RNA as a chain terminator and blocks polyadenylation, disrupting RNA synthesis ^{4,12Reference 4Wei C et al. · 2019Cordycepin inhibits drug-resistant non-small-cell lung cancer progression by activating the AMPK signalling pathwayView study →Reference 12Tuli HS et al. · 2013Cordycepin: a bioactive metabolite with therapeutic potentialView study →}. The problem: being a near-perfect adenosine mimic, it is rapidly deaminated by adenosine deaminase (ADA) to the largely inactive 3’-deoxyinosine, giving a minutes-scale half-life and poor oral bioavailability ^{9Reference 9Qi C et al. · 2023AnimalSimultaneous determination of cordycepin and its metabolite 3’-deoxyinosine in rat whole blood by UHPLC-Q Exactive HRMS and application to pharmacokinetic studyView study →}. That liability has pushed drug development away from the molecule itself and toward a ProTide prodrug, NUC-7738, which is the source of the only human clinical data here ^{11Reference 11Schwenzer H et al. · 2021Clinical trialThe novel nucleoside-analogue ProTide NUC-7738 overcomes cancer resistance mechanisms in vitro and in a first-in-human Phase I clinical trialView study →}. Note up front: the “energy/stamina/libido” reputation belongs to whole cordyceps tradition, not to any isolated-cordycepin study.

1. Anticancer

The marquee application. Cordycepin is incorporated into RNA and terminates chain elongation and polyadenylation, induces apoptosis and cell-cycle arrest via AMPK activation ^{4Reference 4Wei C et al. · 2019Cordycepin inhibits drug-resistant non-small-cell lung cancer progression by activating the AMPK signalling pathwayView study →}, inhibits EGFR/ERK–Slug signalling in lung cancer ^{5Reference 5Hwang JH et al. · 2017Cordycepin induces human lung cancer cell apoptosis by inhibiting nitric-oxide-mediated ERK/Slug signallingView study →}, and reverses cisplatin resistance in non-small-cell lung cancer ^{4Reference 4Wei C et al. · 2019Cordycepin inhibits drug-resistant non-small-cell lung cancer progression by activating the AMPK signalling pathwayView study →}.

Gap: these effect sizes come from cell lines and mouse models; isolated cordycepin has essentially no human efficacy data, and the only clinical signal is from the ProTide prodrug NUC-7738 — not the molecule ^{11Reference 11Schwenzer H et al. · 2021Clinical trialThe novel nucleoside-analogue ProTide NUC-7738 overcomes cancer resistance mechanisms in vitro and in a first-in-human Phase I clinical trialView study →}.

2. Anti-inflammatory

Cordycepin suppresses NF-κB via Akt/p38 in LPS-stimulated macrophages (lowering TNF-α, iNOS and COX-2) ^{1Reference 1Kim HG et al. · 2006Cordycepin inhibits lipopolysaccharide-induced inflammation by suppression of NF-κB through Akt and p38 inhibition in RAW 264.7 macrophage cellsView study →}, drives M1→M2 macrophage repolarisation limiting organ damage in septic mice ^{2Reference 22022AnimalCordycepin induces M1/M2 macrophage polarization to attenuate liver and lung damage in immature septic mice via NF-κB/p65 inhibitionView study →}, reduces pain and joint pathology in osteoarthritis rodents through its polyadenylation-inhibitor action ^{3Reference 3Ashraf S et al. · 2019AnimalThe polyadenylation inhibitor cordycepin reduces pain, inflammation and joint pathology in rodent models of osteoarthritisView study →}, and attenuates airway hyperreactivity in asthma models ^{8Reference 8Yang X et al. · 2015AnimalCordycepin alleviates airway hyperreactivity in a murine model of asthma by attenuating the inflammatory processView study →}.

Gap: consistent and mechanistically coherent, but entirely preclinical, with no human anti-inflammatory trial ^{1,3Reference 1Kim HG et al. · 2006Cordycepin inhibits lipopolysaccharide-induced inflammation by suppression of NF-κB through Akt and p38 inhibition in RAW 264.7 macrophage cellsView study →Reference 3Ashraf S et al. · 2019AnimalThe polyadenylation inhibitor cordycepin reduces pain, inflammation and joint pathology in rodent models of osteoarthritisView study →}.

3. Metabolic / lipid-lowering

Cordycepin prevented hyperglycaemia in alloxan-diabetic mice ^{6Reference 6Ma L et al. · 2015AnimalCordycepin from Cordyceps militaris prevents hyperglycemia in alloxan-induced diabetic miceView study →} and lowered serum lipids in hyperlipidaemic hamsters and rats ^{7Reference 7Gao J et al. · 2011AnimalLipid-lowering effect of cordycepin (3’-deoxyadenosine) from Cordyceps militaris on hyperlipidaemic hamsters and ratsView study →}.

Gap: thin — roughly one study per endpoint, in chemically-induced models, with no dose-response in humans ^{6,7Reference 6Ma L et al. · 2015AnimalCordycepin from Cordyceps militaris prevents hyperglycemia in alloxan-induced diabetic miceView study →Reference 7Gao J et al. · 2011AnimalLipid-lowering effect of cordycepin (3’-deoxyadenosine) from Cordyceps militaris on hyperlipidaemic hamsters and ratsView study →}.

4. Antiviral

The chain-termination and polyadenylation-blockade mechanism gives a plausible broad antiviral rationale, historically studied against retroviral polyadenylation ^{12Reference 12Tuli HS et al. · 2013Cordycepin: a bioactive metabolite with therapeutic potentialView study →}.

Gap: dated and in-vitro only, confounded by the rapid ADA deactivation, with no modern controlled data — keep modest ^{12Reference 12Tuli HS et al. · 2013Cordycepin: a bioactive metabolite with therapeutic potentialView study →}.

Mechanisms

Target / pathway	Effect	Relevant to
RNA polyadenylation / chain termination (incorporated as 3’-dATP; no 3’-OH)	truncates mRNA polyadenylation and transcription	anticancer, anti-inflammatory, antiviral
AMPK activation	energy-stress signalling → apoptosis, growth arrest, resistance reversal	anticancer (NSCLC)
EGFR/ERK–Slug and NO signalling	↓ proliferation, pro-apoptotic	anticancer (lung)
NF-κB via Akt/p38 inhibition	↓ TNF-α, iNOS, COX-2, IL-1β/IL-6	anti-inflammatory, sepsis, asthma
Adenosine A3 receptor (adenosine analogue)	receptor-mediated anti-inflammatory/signalling modulation	anti-inflammatory (reviewed)
mTOR (downstream of AMPK)	autophagy / growth-signal modulation	anticancer (supporting)

Pharmacokinetics

The defining problem. Because cordycepin is a near-perfect adenosine mimic, it is rapidly deaminated by adenosine deaminase (ADA) to the largely inactive 3’-deoxyinosine, giving a very short plasma half-life — rat whole-blood work confirms cordycepin is consumed rapidly with 3’-deoxyinosine as the dominant circulating metabolite ^{9Reference 9Qi C et al. · 2023AnimalSimultaneous determination of cordycepin and its metabolite 3’-deoxyinosine in rat whole blood by UHPLC-Q Exactive HRMS and application to pharmacokinetic studyView study →}. Oral bioavailability of intact cordycepin is poor-to-negligible; one study argues the apparent oral effect may run through a “nucleoside rescue” route, where absorbed 3’-deoxyinosine is re-converted intracellularly to cordycepin triphosphate rather than intact cordycepin surviving first pass ^{10Reference 102019A novel nucleoside rescue metabolic pathway may be responsible for the therapeutic effect of orally administered cordycepinView study →}. Two workarounds define the field: co-administration with an ADA inhibitor (pentostatin) to keep cordycepin intact ^{12Reference 12Tuli HS et al. · 2013Cordycepin: a bioactive metabolite with therapeutic potentialView study →}, and the modern NUC-7738 ProTide prodrug, which bypasses ADA deamination and the rate-limiting first phosphorylation to deliver the active triphosphate intracellularly at far higher potency ^{11Reference 11Schwenzer H et al. · 2021Clinical trialThe novel nucleoside-analogue ProTide NUC-7738 overcomes cancer resistance mechanisms in vitro and in a first-in-human Phase I clinical trialView study →}. The bottom line: intact-cordycepin systemic exposure from oral supplementation is low and fleeting, so efficacy figures from injected or ADA-protected preclinical work do not transfer to oral fruiting-body dosing.

Clinical trials

For isolated cordycepin there are no completed human efficacy trials. Human clinical data exist only for the prodrug NUC-7738, tested in the first-in-human NuTide:701 Phase I study in advanced solid tumours — reported well-tolerated with early signs of anticancer activity ^{11Reference 11Schwenzer H et al. · 2021Clinical trialThe novel nucleoside-analogue ProTide NUC-7738 overcomes cancer resistance mechanisms in vitro and in a first-in-human Phase I clinical trialView study →}. This is a chemically distinct ProTide (much more potent than cordycepin in vitro), engineered specifically to overcome cordycepin’s ADA/pharmacokinetic liabilities, so it is evidence for the scaffold, not for taking cordycepin. Whole-herb cordyceps human trials exist but are not cordycepin-specific and belong to the herb page.

Last checked: July 2026.

Toxicity & Safety

Cordycepin is an antiproliferative/cytotoxic nucleoside analogue — the same RNA-directed activity that makes it an anticancer candidate is intrinsically a genotoxic, antiproliferative liability rather than a benign “tonic” profile ^{4,12Reference 4Wei C et al. · 2019Cordycepin inhibits drug-resistant non-small-cell lung cancer progression by activating the AMPK signalling pathwayView study →Reference 12Tuli HS et al. · 2013Cordycepin: a bioactive metabolite with therapeutic potentialView study →}, which is why this page is flagged moderate and should not inherit the low-risk framing of whole-herb cordyceps. Preclinical data are generally well-tolerated at studied doses, but no formal human safety dossier exists for the isolated molecule (the human tolerability data are for NUC-7738, a different entity) ^{11Reference 11Schwenzer H et al. · 2021Clinical trialThe novel nucleoside-analogue ProTide NUC-7738 overcomes cancer resistance mechanisms in vitro and in a first-in-human Phase I clinical trialView study →}. The interaction surface follows from its adenosine mimicry: ADA inhibitors (pentostatin) and other agents that raise ADA-substrate levels will markedly increase cordycepin exposure and potentiate cytotoxicity; adenosine and adenosine-receptor drugs (dipyridamole, adenosine itself, methylxanthines as receptor antagonists) are plausible pharmacodynamic interactions; and additive risk with cytotoxic chemotherapy is theoretical but expected ^{12Reference 12Tuli HS et al. · 2013Cordycepin: a bioactive metabolite with therapeutic potentialView study →}.

Dosage

There is no established or validated human oral dose for isolated cordycepin, and nothing here is a recommendation. Preclinical rodent studies typically use ~10–60 mg/kg (oral or intraperitoneal), often with ADA protection, which is not human-translatable. Supplements sell Cordyceps militaris extracts standardised to a stated cordycepin content, but purified cordycepin has no clinical dosing standard and its poor oral stability makes any oral figure unreliable. NUC-7738 (the prodrug, given intravenously on a trial-defined escalation) is a separate agent — its dosing is not a cordycepin dose ^{11Reference 11Schwenzer H et al. · 2021Clinical trialThe novel nucleoside-analogue ProTide NUC-7738 overcomes cancer resistance mechanisms in vitro and in a first-in-human Phase I clinical trialView study →}.

References